N-acylhydrazone compounds capable of inhibiting nav1.7 and/or nav1.8, processes for the preparation thereof, compositions, uses, methods for treatment using same, and kits

A compound characterized in that it comprises Formula (I)

• or a pharmaceutically acceptable salt, hydrate, solvate, and isomer thereof, wherein:
• R1 is selected from hydrogen, halogen, branched or linear C1-6 alkyl branched or linear C1-6 alkoxy, morpholin, piperidinyl or substituted piperidinyl, pyridinyl or substituted pyridinyl, piperazin or substituted piperazin, C3-7 heterocycloalkyl, aryloxy, substituted aryloxy, or R7;
• R2 and R3 are independently selected from the group consisting of hydrogen, halogen, linear or branched C1-6 alkyl;
• linear or branched C1-6 alkoxy, amine, C1-6 haloalkyl, aryl, substituted aryl, aryloxy, or substituted aryloxy;
• R4 is selected from the group consisting of hydrogen, halogen, linear or branched C1-6 alkyl;
• linear or branched C1-6 alkoxy, aryl, pyridinyl or substituted pyridinyl, pyridone, saturated or unsaturated C3-7 cycloalkyl saturated or unsaturated C1-5 alkyl substituted C3-7 cycloalkyl saturated or unsaturated halosubstituted C3-7 cycloalkyl, picolinamide or R13;
• R5 and R6 are independently selected from hydrogen or linear or branched C1-6 alkyl.
• R7 is:
• wherein,
• R8 is selected from the group consisting of hydrogen, halogen, linear or branched C1-6 alkyl, linear or branched C1-6 alkoxy, C1-6 haloalkyl, morpholin, C1-6 haloalkyloxy, C1-6 alkylamino or (C1-6 alkylamino) C1-6 alkoxy;
• R9, R11 and R12 are independently selected from the group consisting of hydrogen, halogen, linear or branched C1-6 alkyl, linear or branched C1-6 alkoxy;
• C1-6 haloalkyl or C3-6 cycloalkyloxy;
• R10 is selected from the group consisting of hydrogen, halogen, linear or branched C1-6 alkyl, linear or branched C1-6 alkoxy, C3-6 cycloalkyloxy;
• (C3-6 cycloalkyl) C1-6 alkoxy;
• S—C1-6 alkyl;
• C1-6 alkylamino;
• haloalkyloxy C1-6, haloalkyl C1-6, (C1-6 alkylamino) C1-6 alkoxy, (—S—C1-6 alkyl) C1-6 alkyloxy, C1-6 alkylsulfonylamide, or -OCD3;
• R13 is:
• wherein,
• R14 and R15 are independently selected from the group consisting of hydrogen, halogen, linear or branched C1-6 alkyl;
• linear or branched C1-6 alkoxy, C1-6 haloalkyl, C1-6 alkylamino, C1-6 alkylsufonyl, C1-6 alkylsufonylamide, (C1-6 alkylsufonyl) C1-6 alkyl;
• C1-6 hydroxyalkyl, (C1-6 alkylamino) C1-6 alkoxy, amide, -OCD3;
• or, R14 and R15 are optionally substituted with an OC═N, N—CO or SC═N group forming together a thiazole or an oxazole.
• R16 and R17 are independently selected from the group consisting of hydrogen, halogen, linear or branched C1-6 alkyl;
• linear or branched C1-6 alkoxy, C1-6 haloalkyl, C1-6 alkylamino, C1-6 alkylsufonylamide, (C1-6 alkylamino) C1-6 alkyl or -OCD3;
• R18 is selected from the group consisting of hydrogen, halogen, linear or branched C1-6 alkyl or linear or branched C1-6 alkoxy.